» Articles » PMID: 33921274

Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach

Overview
Journal Metabolites
Publisher MDPI
Date 2021 Apr 30
PMID 33921274
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the great progress made in insulin preparation and titration, many patients with diabetes are still experiencing dangerous fluctuations in their blood glucose levels. This is mainly due to the large between- and within-subject variability, which considerably hampers insulin therapy, leading to defective dosing and timing of the administration process. In this work, we present a nonlinear mixed effects model describing the between-subject variability observed in the subcutaneous absorption of fast-acting insulin. A set of 14 different models was identified on a large and frequently-sampled database of lispro pharmacokinetic data, collected from 116 subjects with type 1 diabetes. The tested models were compared, and the best one was selected on the basis of the ability to fit the data, the precision of the estimated parameters, and parsimony criteria. The selected model was able to accurately describe the typical trend of plasma insulin kinetics, as well as the between-subject variability present in the absorption process, which was found to be related to the subject's body mass index. The model provided a deeper understanding of the insulin absorption process and can be incorporated into simulation platforms to test and develop new open- and closed-loop treatment strategies, allowing a step forward toward personalized insulin therapy.

Citing Articles

The Minimally-Invasive Oral Glucose Minimal Model: Estimation of Gastric Retention, Glucose Rate of Appearance, and Insulin Sensitivity From Type 1 Diabetes Data Collected in Real-Life Conditions.

Faggionato E, Schiavon M, Ekhlaspour L, Buckingham B, Dalla Man C IEEE Trans Biomed Eng. 2023; 71(3):977-986.

PMID: 37844003 PMC: 10973685. DOI: 10.1109/TBME.2023.3324206.


Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility.

Cobelli C, Kovatchev B J Diabetes Sci Technol. 2023; 17(6):1493-1505.

PMID: 37743740 PMC: 10658679. DOI: 10.1177/19322968231195081.


Nonlinear Mixed Effects Modeling of Glucagon Kinetics in Healthy Subjects.

Faggionato E, Laurenti M, Vella A, Dalla Man C IEEE Trans Biomed Eng. 2023; 70(9):2733-2740.

PMID: 37030857 PMC: 10509356. DOI: 10.1109/TBME.2023.3262974.


Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study.

Lachal S, Tourki Y, Franc S, Huneker E, Charpentier G, Benhamou P J Diabetes Sci Technol. 2021; 17(1):176-185.

PMID: 34658265 PMC: 9846416. DOI: 10.1177/19322968211046021.

References
1.
Ette E, Williams P . Population pharmacokinetics II: estimation methods. Ann Pharmacother. 2004; 38(11):1907-15. DOI: 10.1345/aph.1E259. View

2.
Toffolo G, Campioni M, Basu R, Rizza R, Cobelli C . A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab. 2005; 290(1):E169-E176. DOI: 10.1152/ajpendo.00473.2004. View

3.
Heinemann L . Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002; 4(5):673-82. DOI: 10.1089/152091502320798312. View

4.
Brange J, Owens D, Kang S, Volund A . Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990; 13(9):923-54. DOI: 10.2337/diacare.13.9.923. View

5.
Kovatchev B, Breton M, Dalla Man C, Cobelli C . In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009; 3(1):44-55. PMC: 2681269. DOI: 10.1177/193229680900300106. View